Literature DB >> 33407177

Central lymph node metastasis is predictive of survival in advanced gastric cancer patients treated with D2 lymphadenectomy.

Huiwen Lu1, Bochao Zhao1, Rui Huang2, Yimeng Sun1, Zirui Zhu1, Huimian Xu1, Baojun Huang3.   

Abstract

BACKGROUND: The number of positive lymph nodes, which was defined as "N stage", is mostly used to predict the survival of D2-resected gastric cancer patients, not the location. A "central lymph node" (CnLN) was defined by Ikoma et al., included common hepatic, celiac and proximal splenic artery LNs. CnLNs located in the extraperigastric area are included in the D2 LN station for gastric cancer. We speculate that CnLNs can be regarded as a predictor of survival.
METHODS: Eligible advanced gastric cancer patients who underwent curative resection and D2 lymph node dissection between 2004 and 2012 at our institution were identified. The frequency of CnLN metastases and risk factors affecting DFS were examined. Survival differences were assessed by log-rank tests and Kaplan-Meier curves.
RESULTS: The study identified 1178 patients who underwent curative surgery or D2 or more extensive lymphadenectomy. A total of 342 patients had been proven to have CnLN metastasis. Larger tumor size (P < 0.001), more frequent lymphatic vessel invasion (P < 0.001), signet ring cell histology (P = 0.014), and more advanced pathological T stage (P = 0.013) were significantly related to CnLNs metastasis. The patients with CnLN metastasis had a poor prognosis (HR for DFS of 1.366, 95%CI = 1.138-1.640, P = 0.001). For the pN2/3 patients, CnLN metastasis was associated with shorter 5-year DFS (for pN2 patients: 25.9% vs 39.3%, P = 0.017; for pN3 patients: 11.5% vs 23.4%, P = 0.005).
CONCLUSION: Gastric cancer patients with CnLN metastasis who underwent D2 resection had a poor prognosis. With the same N stage, the patients with positive CnLNs had shorter survival. CnLNs metastasis could be a supplement to N stage and a predictor of survival in gastric cancer patients. Large sample, multicenter, randomized clinical trials are still needed in the future.

Entities:  

Keywords:  D2 lymphadenectomy; Gastric cancer; Lymph node metastasis; Survival

Mesh:

Year:  2021        PMID: 33407177      PMCID: PMC7789278          DOI: 10.1186/s12876-020-01578-4

Source DB:  PubMed          Journal:  BMC Gastroenterol        ISSN: 1471-230X            Impact factor:   3.067


  27 in total

1.  Lymph node staging in gastric cancer: is location more important than Number? An analysis of 1,038 patients.

Authors:  M S Karpeh; L Leon; D Klimstra; M F Brennan
Journal:  Ann Surg       Date:  2000-09       Impact factor: 12.969

2.  Superiority of a new UICC-TNM staging system for gastric carcinoma.

Authors:  H Hayashi; T Ochiai; T Suzuki; H Shimada; S Hori; A Takeda; Y Miyazawa
Journal:  Surgery       Date:  2000-02       Impact factor: 3.982

3.  The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging.

Authors:  Mahul B Amin; Frederick L Greene; Stephen B Edge; Carolyn C Compton; Jeffrey E Gershenwald; Robert K Brookland; Laura Meyer; Donna M Gress; David R Byrd; David P Winchester
Journal:  CA Cancer J Clin       Date:  2017-01-17       Impact factor: 508.702

4.  Results of a nation-wide retrospective study of lymphadenectomy for esophagogastric junction carcinoma.

Authors:  Hiroharu Yamashita; Yasuyuki Seto; Takeshi Sano; Hiroyasu Makuuchi; Nobutoshi Ando; Mitsuru Sasako
Journal:  Gastric Cancer       Date:  2016-10-28       Impact factor: 7.370

5.  Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial.

Authors:  Jeeyun Lee; Do Hoon Lim; Sung Kim; Se Hoon Park; Joon Oh Park; Young Suk Park; Ho Yeong Lim; Min Gew Choi; Tae Sung Sohn; Jae Hyung Noh; Jae Moon Bae; Yong Chan Ahn; Insuk Sohn; Sin Ho Jung; Cheol Keun Park; Kyoung-Mee Kim; Won Ki Kang
Journal:  J Clin Oncol       Date:  2011-12-19       Impact factor: 44.544

6.  Clinical implications of the histologically and immunohistochemically detected solitary lymph node metastases in gastric cancer.

Authors:  J Griniatsos; E Yiannakopoulou; H Gakiopoulou; A Alexandrou; N Dimitriou; I Karavokyros; E Felekouras
Journal:  Scand J Surg       Date:  2011       Impact factor: 2.360

7.  Skip lymph node metastasis in gastric cancer: is it skipping or skipped?

Authors:  Yoon Young Choi; Ji Yeong An; Ali Guner; Dae Ryong Kang; In Cho; In Gyu Kwon; Hyun Beak Shin; Woo Jin Hyung; Sung Hoon Noh
Journal:  Gastric Cancer       Date:  2015-02-24       Impact factor: 7.370

8.  Evaluation of the New International Union Against Cancer TNM staging for gastric carcinoma.

Authors:  H Katai; K Yoshimura; K Maruyama; M Sasako; T Sano
Journal:  Cancer       Date:  2000-04-15       Impact factor: 6.860

9.  Efficacy of preoperative chemotherapy regimens in patients with initially unresectable locally advanced gastric adenocarcinoma: capecitabine and oxaliplatin (XELOX) or with epirubicin (EOX).

Authors:  Yan Wang; Rong-Yuan Zhuang; Yi-Yi Yu; Shan Yu; Jun Hou; Yuan Ji; Yi-Hong Sun; Kun-Tang Shen; Zhen-Bin Shen; Feng-Lin Liu; Nai-Qing Zhao; Tian-Shu Liu
Journal:  Oncotarget       Date:  2016-11-15

10.  A phase II trial of Xeloda and oxaliplatin (XELOX) neo-adjuvant chemotherapy followed by surgery for advanced gastric cancer patients with para-aortic lymph node metastasis.

Authors:  Yan Wang; Yi-yi Yu; Wei Li; Yi Feng; Jun Hou; Yuan Ji; Yi-hong Sun; Kun-tang Shen; Zhen-bin Shen; Xin-yu Qin; Tian-shu Liu
Journal:  Cancer Chemother Pharmacol       Date:  2014-04-21       Impact factor: 3.333

View more
  2 in total

1.  Surgeon-Pathologist Team Approach Dramatically Affects Lymph Nodes Detection and Improves Patients' Short-Term Outcome.

Authors:  Maria Raffaella Ambrosio; Bruno Perotti; Alda Battini; Caterina Fattorini; Andrea Cavazzana; Rocco Pasqua; Piergaspare Palumbo; Liano Gia; Marco Arganini
Journal:  Cancers (Basel)       Date:  2022-02-18       Impact factor: 6.639

2.  Mutation of MUC16 Is Associated With Tumor Mutational Burden and Lymph Node Metastasis in Patients With Gastric Cancer.

Authors:  Fengxiang Zhang; Xianzhe Li; Huaxian Chen; Jianping Guo; Zhizhong Xiong; Shi Yin; Longyang Jin; Xijie Chen; Dandong Luo; Haijie Tang; Chaobin Mao; Lei Lian
Journal:  Front Med (Lausanne)       Date:  2022-02-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.